ERBB2 and breast cancer: We proved that CDKN1A loss-of-function mimicked the effect of miR-146a-5p overexpression upon reducing the response to trastuzumab, increasing proliferation and migration, and inducing cell cycle promotion on HER2+ BC cells and increasing angiogenesis in HUVEC-2 cells.